Lecture by Dr Sujoy Dasgupta in BOGSCON 2015, the Annual Conference of Bengal Obstetric and Gynaecological Society, held at Hotel Novotel, Kolkata in January, 2015; where he had been invited as FACULTY to deliver his lecture
Thromboprophylaxis in pregnancy and puerperiumManju Puri
This presentation is about thromboprophylaxis in pregnancy and puerperium and describes the risk assessment , indications, drugs to be used, when to start, for how long to continue.
Ovarian Hyperstimulation Syndrome(OHSS), is a Rare iatrogenic complication of ovarian stimulation occurring during the luteal phase or during early pregnancy where a patient's ovaries become swollen and fluid builds up around her abdomen
Thromboprophylaxis in pregnancy and puerperiumManju Puri
This presentation is about thromboprophylaxis in pregnancy and puerperium and describes the risk assessment , indications, drugs to be used, when to start, for how long to continue.
Ovarian Hyperstimulation Syndrome(OHSS), is a Rare iatrogenic complication of ovarian stimulation occurring during the luteal phase or during early pregnancy where a patient's ovaries become swollen and fluid builds up around her abdomen
ESHRE Guideline on Recurrent Pregnancy Loss (RPL)Sujoy Dasgupta
Dr Sujoy Dasgupta invited to deliver a lecture on "RPL- ESHRE Guideline" in the Annual Conference of RCOG (Royal College of Obstetricians and Gynaecologists) IRC (International Representative Committee) India East held on 20-21 May, 2023
The role of uterine artery embolization in gynecology practiceApollo Hospitals
Uterine artery embolization (UAE) is a minimally invasive interventional radiological procedure to occlude the arterial
supply to the uterus. UAE has been very useful for controlling hemorrhage following delivery/abortion, in ectopic or cervical pregnancy, gestational trophoblastic disease or carcinoma cervix. Currently it is being mostly used for treating uterine fibroids. It requires a shorter Hospital stay with early resumption to normal activity. This review briefly summarizes the role of this relatively new technique in gynecologic practice.
Fetal growth restriction (FGR), formerly called intrauterine growth restriction (IUGR), refers to a condition in which an unborn baby is smaller than it should be because it is not growing at a normal rate inside the womb.
Mild FGR usually doesn't cause long-term problems. In fact, most babies who have it catch up in height and weight by age 2. But severe FGR can seriously harm a baby before and after birth. The extent of the problems depends on the cause and how severe the growth restriction is. It also depends on what point in the pregnancy it starts.
THIS WAS PRESENTED AT SAFOG MOGS "SMART CONFERENCE "IN MUMBAI
PREPARED WITH HELP OF DR SUCHITRA PANDIT,DR CN PURANDARE AND DR ALPESH GANDHI.....VIDEOS CAN BE SEEN AT U TUBE
ESHRE Guideline on Recurrent Pregnancy Loss (RPL)Sujoy Dasgupta
Dr Sujoy Dasgupta invited to deliver a lecture on "RPL- ESHRE Guideline" in the Annual Conference of RCOG (Royal College of Obstetricians and Gynaecologists) IRC (International Representative Committee) India East held on 20-21 May, 2023
The role of uterine artery embolization in gynecology practiceApollo Hospitals
Uterine artery embolization (UAE) is a minimally invasive interventional radiological procedure to occlude the arterial
supply to the uterus. UAE has been very useful for controlling hemorrhage following delivery/abortion, in ectopic or cervical pregnancy, gestational trophoblastic disease or carcinoma cervix. Currently it is being mostly used for treating uterine fibroids. It requires a shorter Hospital stay with early resumption to normal activity. This review briefly summarizes the role of this relatively new technique in gynecologic practice.
Fetal growth restriction (FGR), formerly called intrauterine growth restriction (IUGR), refers to a condition in which an unborn baby is smaller than it should be because it is not growing at a normal rate inside the womb.
Mild FGR usually doesn't cause long-term problems. In fact, most babies who have it catch up in height and weight by age 2. But severe FGR can seriously harm a baby before and after birth. The extent of the problems depends on the cause and how severe the growth restriction is. It also depends on what point in the pregnancy it starts.
THIS WAS PRESENTED AT SAFOG MOGS "SMART CONFERENCE "IN MUMBAI
PREPARED WITH HELP OF DR SUCHITRA PANDIT,DR CN PURANDARE AND DR ALPESH GANDHI.....VIDEOS CAN BE SEEN AT U TUBE
Deep Vein Thrombosis is an important and frequently missed out diagnosis that can often lead to sudden death in post operative patients. Did this powerpoint for an O&G seminar. Mainly focusses on DVT in OBG and its management and prevention. Kindly leave a comment and let me know what you think.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Dr Sujoy Dasgupta was invited to deliver a lecture on "Male Infertility, Antioxidants and Beyond" on 3 February in Yuvacon 2024 organized by the Bengal Obstetric and Gynaecological Society (BOGS). The session was supported by UNS.
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
Dr Sujoy Dasgupta participated in an invited debate FOR the motion "Radical excision of DIE in subferile women with deep infiltrating endometriosis is not recommended" in ENDOGYN 2024, organized by the IAGE (Indian Association of Gynaecological Endoscopists) and the BOGS (Bengal Obstetric and Gynaecological Society) on 10 February 2024.
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
Invited lecture by Dr Sujoy Dasgupta in the Ultrasound Workshop of the Annual National Conference of Indian Association of Gynaecological Endoscopists (IAGE) held on 15 March 2024 at the Taj Ganges, Varanasi
Invited lecture by Dr Sujoy Dasgupta on "Azoospermia - Evaluation and Management" in a CME on "Standardising Male Factor Evaluation" organised by Indian Fertility Society (IFS) on 20 January 2024.
Are we giving much importance to AMH in infertility practice?Sujoy Dasgupta
Dr Sujoy Dasgupta delivered "Kamini Rao Oration" on "Are we giving much importance to AMH in infertility practice?" in East Zone Yuva FOGSI Conference organized by Imphal Obstetric and Gynaecological Society (IOGS) on 24 December, 2023
Male Infertility-How a Gynaecologist can Manage?Sujoy Dasgupta
Dr Sujoy dasgupta delivered an invited lecture on "Male Infertility-How a Gynaecologist can Manage?" in a CME on "New Frontiers in Infertility" organized by Genome Fertility Centre and Bhagirathi Neotia Woman and Child Care Centre, Kolkata held on 15 December 2023
Endometriosis and Subfertility, Primium non nocereSujoy Dasgupta
Dr Sujoy dasgupta and Dr Arun Madhab Barua were invited to moderate a panel discussion on "Endometriosis and Subfertility, Primium non nocere" in the International Congress on Endometriosis (ICE) on 10 December 2023 at Dhana Dhanya Auditorium, Kolkata
Dr Sujoy Dasgupta delivered an invited talk on "Embryo Transfer" in "Ultrasound Workshop" on 8 December 2023 at Milan, 2023, the conference of all the Obstetric and Gynaecological Societies of West Bengal. This conference was organized by Kalyani Obstetric and Gynaecological Society (KOGS).
Rational Investigations and Management of Male InfertilitySujoy Dasgupta
Dr Sujoy Dasgupta delivered an invited lecture in the annual conference of WMOGS (West Midnapore Obstetric and Gynaecological Society) held on 16 September, 2023
Endometriosis and Subfertility - What to do?Sujoy Dasgupta
Lecture delivered by Dr Sujoy Dasgupta in IPCON 2823, the Mid term conference of ISOPARB (Indian Society of Perinatology and Reproductive Biology) held at Kolkata on 10 September
IVF- How it changed the perspective of Male InfertilitySujoy Dasgupta
Dr Sujoy Dasgupta was invited to deliver a talk in a CME held on the World IVF Day (25 July, 2023) organized by Burdwan Obst Gynae Society and Corona Remedies.
Male Infertility- How Gynaecologists can manage?Sujoy Dasgupta
Dr Sujoy Dasgupta delivered an invited lecture in a CME organised by JB Pharma with the support from West Midnapore Obst and Gynae Society and Genome Fertility Centre held at Medinipur on 22 July, 2023.
Role of Multivitamins & Antioxidants in Managing Male Infertility Sujoy Dasgupta
Dr Sujoy Dasgupta was invited to deliver a talk on "Role of Multivitamins & Antioxidants in Managing Male Infertility " in a CME organized by Agartala Obstetric and Gynaecological Society and ArEx Laboratory held at Agartala on 8 July 2023
Panel discussion moderated by Dr Sujoy Dasgupta and Dr Sudip Basu on "Troubleshooting in Male Subfertility" in the Andrology Workshop organized by Special Interest Group (SIG) Andrology and Indian Fertility Society (IFS) West Bengal Chapter held on 11 June 2023 at Kolkata
Fertility Management: Synergy between Endoscopists and Fertility SpecialistsSujoy Dasgupta
Dr Sujoy Dasgupta was invited to moderate a panel discussion on "Fertility Management: Synergy between Endoscopists and Fertility Specialists " in a CME by Torrent held on 27 May 2023.
Invited lecture by Dr Sujoy Dasgupta on "Abnormal Semen- What Next" in a CME organized by HBC Life Sciences on "Fertility and Beyond" held on 28 April 2023
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
3. Venous Thromboembolism (VTE)
• Incidence- 2.3 per 1000 pregnancy
• Risk increases 4-6 fold in pregnancy
• Risk increases further in puerperium (especially the 1st
week)
• Overall case fatality rate- 3.5%
• The mortality rate of PE is 11% within an hour of presentation
and a further 30% among survivors if not recognized.
• Often no time for diagnosis and treatment
• Globally- 3% of maternal deaths (WHO, 2014)
Prevention- THROMBO-PROPHYLAXIS
4.
5. Risk Factors for VTE*
Pre-existing Previous venous thromboembolism
Thrombophilia: Hereditary (Deficiency of antithrombin, Protein S, Protein C; Mutation of Factor V Leiden,
Prothrombin G20210A), Acquired (Anti-Phospholipid Syndrome)
Medical comorbidities (e.g. heart or lung disease, SLE, cancer, inflammatory conditions , nephrotic
syndrome (proteinuria > 3 g/day), sickle cell disease, intravenous drug user
Age > 35 years
Obesity (BMI > 30 kg/m2) either pre-pregnancy or in early pregnancy
Parity ≥ 3
Smoking
Gross varicose veins (symptomatic or above knee or with associated phlebitis, oedema/skin changes)
Paraplegia
Obstetric Multiple pregnancy, assisted reproductive therapy
Pre-eclampsia
Caesarean section
Prolonged labour, mid-cavity rotational operative delivery
PPH (> 1 litre) requiring transfusion
New-onset/transient)
Potentially reversible
Surgical procedure in pregnancy or puerperium (e.g. ERPC, appendicectomy, postpartum
sterilisation)
Hyperemesis, dehydration
Ovarian hyperstimulation syndrome
Admission or immobility (≥ 3 days’ bed rest) e.g. symphysis pubis dysfunction restricting mobility
Systemic infection (requiring antibiotics or admission to hospital)
Long-distance travel (> 4 hours)
*
RCOG Green-top Guidelines No. 37a, November 2009 Reducing the risk of thrombosis and embolism during pregnancy and the puerperium
6. When to Assess
• Preconceptional Care
• First Antenatal visit
• Intrapartum period
• Immediate postpartum
• If admitted to hospital for any reason
• If develops intercurrent problems (e.g.,
infection)
7. Risk Scoring
Pre-existing Score Obstetric Score Transient Score
Previous recurrent VTE 3 Pre-eclampsia 1 Any Surgery 2
Previous VTE – unprovoked/
estrogen related
3 Dehydration/
Hyperemesis/OHSS
1 Current
Infection
1
Previous VTE – provoked 2 Multiple pregnancy/ ART 1 Immobility 1
Family history of VTE 1 CS in labour 2
Known thrombophilia 2 Elective CS 1
Medical comorbidities 2 Mid-cavity/ rotational
forceps
1
Age (> 35 years) 1 Prolonged labour (>24 hrs) 1
Obesity (BMI >40 kg/m2
) 2 PPH (>1 litre or transfusion) 1
Obesity (BMI >30kg/m2
) 1
Parity ≥3 1
Smoker 1
Gross varicose veins 1
9. Heparin
Unfractionated
Heparin (UFH)
Low Molecular Weight
Heparin (LMWH)
Molecular weight 12,000-16,000 Da 3000-7000
Inhibitory effect F Xa, F IIa F Xa mainly
Bioavailability 20-30% 70-80%
aPTT Prolonged Not prolonged
Complications (Bleeding,
Osteoporosis)
Common Rare
Heparin Induced
Thrombocytopenia (HIT)
3-5% Never occurs de novo
Half life 30 min 3 hour
Anticoagulant action Shorter Prolonged (Once daily
dose)
Cost Cheaper Expensive
10. Prophylactic Dose Calculation
Weight (Kg) Enoxaparin Dalteparin Tinzaparin
(75 U/kg/day)
<50 20 mg OD 2500 U OD 3500 U OD
50-90 40 mg OD 5000 U OD 4500 U OD
91-130 60 mg OD*
7500 U OD*
7000 U OD*
131-170 80 mg OD*
10,000 U OD*
9000 U OD*
>170 0.6 mg/kg/day*
75 U/kg/day*
75 U/kg/day*
*
May be given in two divided doses
11. Higher dose
• Recurrent VTE, who were on long term oral anticoagulants
• Antithrombin III deficiency
• Homozygous Factor V Leiden Mutation
• Homozygous Prothrombin G20210A Mutation
• Double heterozygous defect (FVL, G20210A)
• APLA syndrome with H/O VTE
Enoxaparin Dalteparin Tinzaparin
High
Prophylactic/
Intermediate
Dose
40 mg 12 hourly 5000 U 12 hourly 4500 U 12 hourly
(Weight 50-90 kg)
Adjusted/
Therapeutic Dose
Antenatal-
1 mg/kg/ 12
hourly
Postnatal-
1.5 mg/kg/daily
Antenatal-
100 U/kg/12
hourly
Postnatal-
200 U/kg/daily
175 /kg/daily
(Antenatal and
Postnatal)
12. Monitoring
1. Platelet
count
•No previous exposure
to UFH
Not required
•Past/ recent use of
UFH
Every 2-3 days from D4-
D14
2. Anti-Xa •Prophylactic dose Not required
if renal function is normal
(Creatinine clearance >30
ml/min)
•Therapeutic dose •Extreme of body weight
(<50 kg, >90 kg)
•Renal compromise
•Risk factors for bleeding
14. 1. Gap between last dose of
UFH/ LMWH and
Regional anesthesia
12 hours (prophylactic
dose)
24 hours (therapeutic
dose)
2. Restart LMWH/ UFH-
4 hours after removal of
epidural catheter or SA
4 hours after operation
Sunday
6 PM
LMWH 40
mg SC
}>12 hrsMonday
8 AM
Elective CS
under EA
Monday
2 PM
Remove
epidural
catheter
}4 hrs
Monday
6 PM
LMWH 40 mg
SC
15. Alternative to Heparin
Danaparoid Preferred drug in HIT
Lepirudin •Antenatal- Better avoided
•Postnatal- Alternative to danaparoid
Fondaparinux Better to be avoided
Warfarin •Antenatal- 5% risk of embryopathy, if used in 6-9
weeks, at dose >5 mg/day
•Postnatal- Preferred to LMWH, if prophylaxis is
needed for >7 days
Rivaroxaban
Apixaban
Inadequate data
Dabigatran
Ximelgatran
Inadequate data
Dextran Can cause anaphylaxis
18. Previous history of RECURRENT episodes of VTE
Antenatal Postnatal
On long term anticoagulant Adjusted or 75% Therapeutic
dose of LMWH
Long term anticoagulants
Not on long term
anticoagulant
Prophylactic or Intermediate
dose LMWH
6 wk LMWH/ Warfarin
Previous history of SINGLE episode of VTE
Antenatal Postnatal
1. Unprovoked
2. Estrogen related
3. Hereditary
thrombophilia
4. Positive family H/O VTE
Prophylactic dose LMWH 6 wk LMWH/ Warfarin
Associated APLA syndrome Adjusted or 75%
Therapeutic dose of LMWH
+ Aspirin
Long term anticoagulants
Related to transient risk
factors no longer present
Vigilance 6 wk LMWH/ Warfarin
19. Asymptomatic Thrombophilia (no previous history of VTE)
Antenatal Postnatal
Antithrombin III deficiency Adjusted or 75% Therapeutic
dose of LMWH
Long term anticoagulants
1. Homozygous
Factor V
Leiden
2. Homozygous
Prothrombin
G20210A
3. Double
heterozygous
defects (FVL +
G20210A)
Positive
Family
H/O VTE
Prophylactic/ Intermediate
dose LMWH
6 wk LMWH/ Warfarin
No family
H/O VTE
Vigilance 6 wk LMWH/ Warfarin
Other hereditary
thrombophilia
Vigilance 7 days LMWH
APLA syndrome (with H/O
Obstetric complications)
Prophylactic dose LMWH +
Aspirin
6 wk LMWH/ Warfarin
APLA seropositivity only, no
Obst H/O, no thrombosis
Vigilance 7 days LMWH
21. • 1st
trimester:
1. If on low dose warfarin (<5 mg/day)- Consider
continuation of warfarin (ESC, 2011)
2. High risk of VTE (Older generation in mitral
position, past H/O VTE)- Continue Warfarin
(ACCP, 2012)
3. In other cases- Consider replacement of warfarin
by LMWH or UFH (ACCP, 2012)
• 2nd
and 3rd
trimester:
1. Warfarin and replace by UFH close to term (ESC,
2011)
2. Any one of Warfarin, LMWH or UFH (ACCP,
2012)
• After delivery:
Resume anticoagulant 4-6 hour after delivery
(ACCP 2012, ESC 2011)
23. Indian J Urol 2009;25:11-16
REVIEW ARTICLE
Venous thromboembolism: A
problem in the Indian/Asian
population?
Sunil Agarwal, Arvind Dhas Lee, Ravish
Sanghi Raju, Edwin Stephen
Conclusion- Venous thromboembolism (VTE) is a
common and potentially life threatening condition. It
continues to be under diagnosed and undertreated.
Awareness among Indians
regarding this potentially life-
threatening disease is low.
Contrary to earlier belief, the
incidence of VTE in Asia and
India is comparable to that in
Western countries. The prevailing belief
that VTE in the Asian population is less than in the
Western population has essentially been disproved
and there appears no reason to believe that it should
be any different in India.
Pulmonary Thromboembolism:
Indian Scenario
BNBM Prasad
CONCLUSION- In India, VTE is a common cause of
mortality and morbidity in patients hospitalized for
surgical or medical illnesses. It is often misdiagnosed and
not treated in time. Worldwide it ranks among three big
cardiovascular killers. Though the exact
magnitude of problem is not known in
India, the clinical relevance and
incidence is not expected to be
different from Western countries. Signs
and symptoms are nonspecific and high degree of clinical
suspicion with right application of diagnostic tools both
imaging and nonimaging are vital for definitive
diagnosis. pFuture will witness almost total prevention of
VTE in hospitalized patients and application of novel
pharmacological and interventional techniques for
optimizing therapy. .
24. International Journal of Biological & Medical Research
Journal homepage: www.biomedscidirect.com
Original Article
Maternal Mortality at a Tertiary Care Teaching Hospital of Rural India: A
Retrospective Study
Vidyadhar B. Bangal, Purushottam A. Giri, Ruchika Garg
Pulmonary embolism is the third most common direct cause of
maternal mortality (10.59% deaths) after haemorrhage and
eclampsia
25. Original Article
Deep venous thrombosis in the
antenatal period in a large
cohort of pregnancies from
western India
Sonal Vora, Kaniaksha Ghosh,
Shrimati Shettv, Vinita Salvi, and
Purnima Santoskar
Conclusion- We conclude that
the prevalence of DVT in
India is more or less similar
to other reports published (1
in 1000) and both acquired and
heritable thrombophilia show
strong association with DVT
associated with pregnancy.
Thromb J. 2007; 5: 9
J Obstet Gynaecol India.
Dec 2013; 63(6): 373–377
Original Article
Safety and Efficacy of Low
Molecular Weight Heparin
Therapy During Pregnancy:
Three Year Experience at a
Tertiary Care Center
Nilanchali Singh, Priva Varshnev, Reva
Tripathi, Y. M. Mala, and Shakun
Tyagi
Conclusion- Low molecular
weight heparin can be used in
pregnancy for various
indications as an alternative to
unfractionated heparin or
warfarin as it is efficacious and
safe.
26. Conclusion
• Pregnancy itself is a
thrombogenic condition
• Every woman should be
assessed for risk factors
• Decision for
thromboprophylaxis should be
individualized
• LMWH is the drug of choice
• Threshold for recommending
thromboprophylaxis should be
lower because the risk is higher
and the duration is shorter